LifeLoc Technologies Inc (LCTC)

[pdicamillo1]

Key Takeaways from quarterly report:

Total Assets = $8,585,355
Lifeloc has $3.50/share in assets

Revenues were down for the quarter - In my personal opinion, this should not be happening and is a complete disappointment. Every segment that Lifeloc participates in is screaming with growth. As shareholders, we should expect at minimum in line growth with the overall sector. No excuses.

Net income was higher year over year and I would expect this to continue throughout the quarters. I still fully expect total year end 2019 revenues to be over $10 Million. Everything should be in place to exceed this number.

The SpinDx™ platform has the potential to improve real-time screening for a panel of high-abuse drugs, with the ability to efficiently and quantitatively measure relatively low concentrations of drugs such as cocaine, heroin, methamphetamine and other high-abuse drugs. We intend to use this technology, sometimes referred to as "Lab on a Disk", to develop devices and tests that could be used at roadside, emergency rooms and in workplace testing to get a rapid and quantitative measure for a panel of such drugs of abuse. We have detected delta-9-THC (the primary psychoactive component of marijuana) down to concentrations of 5 nanograms per milliliter in our laboratory. This includes resolving the psychoactive delta-9-THC from its inactive metabolites, an important step in establishing impairment. We upgraded our base breathalyzer platform in 2018, and we remain committed to combining it with the SpinDx™ technology. Our goal is to use this combination to develop a THC breathalyzer.

The R.A.D.A.R.® device was designed to be part of an offender supervision program as an alternative to incarceration, and it is assigned to offenders as a condition of parole or probation, with random testing throughout the day to demonstrate that they are meeting the conditions of their sentence. We completed upgrading our base breathalyzer product in Q4 of 2018 and are nearing completion of work in improving the manufacturability of R.A.D.A.R.® devices, which we expect to launch in the first half of 2019.

Going forward, we intend to focus our development efforts on products we believe offer the best prospects to increase our intermediate and near-term revenues.

Our 2019 operating plan is focused on growing sales, increasing gross profits, and increasing research and development efforts on new products for long term growth.